logo

Agenus Inc. (AGEND)



Trade AGEND now with
  Date
  Headline
2/9/2021 8:46:37 AM Agenus Announces Addl Confirmed Objective Clinical Responses From Phase 1/2 Trial Of AGEN1181
10/13/2020 8:46:09 AM Agenus Adds Susan Hirsch To Board
9/18/2020 8:37:37 AM Agenus Begins Rolling Submission Of BLA To FDA For Balstilimab
8/6/2020 7:45:21 AM Agenus Q2 Net Loss $48.2 Mln Or $0.28/shr Vs. Net Loss $51.9 Mln Or $0.38/shr Last Year
6/22/2020 7:15:03 AM Agenus And Betta Pharma Enter License Agreement For Balstilimab And Zalifrelimab In Greater China
6/2/2020 8:34:14 AM Agenus Says FDA Clears IND For INKT Cells To Treat COVID-19 Patients
5/14/2020 8:23:08 AM Agenus Presents Data On AGEN1181 At ASCO Virtual Scientific Program
5/13/2020 10:02:48 AM Agenus : FDA Clears AgenTus IND For Allogeneic INKT Cell Therapy
3/12/2020 7:47:42 AM Agenus Gets Fast Track Designation For Balstilimab Plus Zalifrelimab In Advanced Cervical Cancer
3/12/2020 7:41:32 AM Agenus Q4 Net Loss $31 Mln Or $0.22/Shr Vs Net Loss $49 Mln Or $0.40/Shr Prior Year
3/10/2020 9:18:42 AM Agenus Announces Triggering Of $15.1 Mln Milestone Payment From HealthCare Royalty Partners
2/20/2020 9:58:19 AM Agenus Announces Positive Interim Data From Balstilimab And Zalifrelimab Trials In Second-Line Cervical Cancer
1/9/2020 11:01:24 AM Agenus Appoints Jennifer Buell As President And COO
1/8/2020 8:33:05 AM Agenus Begins Phase 1 Trial With AGEN1223
12/19/2019 7:31:45 AM Agenus Commences Combination Trial Of Its Next-Gen CTLA-4 With Its PD-1 Antibody
11/4/2019 7:25:59 AM Agenus Expect Clinical Readouts From Six Separate Antibody Programs In 2020
7/18/2019 2:30:44 PM Agenus Appoints Don Vidic As VP And Head Of Commercial